Deutscher, Daniel
Weil, Clara
Chodick, Gabriel
Tsukinovsky, Sveta
Bodger, Keith
Waterman, Matti
Kariv, Revital
Article History
Received: 20 June 2022
Accepted: 4 January 2023
First Online: 13 January 2023
Declarations
:
: The MHS research committee and the institutional review board approved the study (IRB#: 0103-18-BBL) and provided an exempt status from the need to complete a formal consent form as described above.
: Not applicable. The manuscript, including related data, figures and tables, has not been previously published and is not under consideration elsewhere.
: This project was supported by an institutional grant from Takeda Pharmaceutics to Maccabi Healthcare Services and did not include the medical writing by the Maccabi authors. Tsukinovsky is an employee of Takeda Pharmaceuticals. Takeda’s employees do not have any stock or stock options. Deutscher, Weil, and Chodick do not have any conflicts of interest. Waterman and Kariv provide consultation for Takeda Pharmaceutics, Petach Tikva, Israel. All authors declare they have no other financial or conflicts of interests related to this study.